Susceptibility of 64 clinical isolates of Neisseria gonorrhoeae to metronidazole was determined by the agar dilution technique using Mueller-Hinton and chocolate agar media. All isolates were resistant to metronidazole at 12.5 jig/ml in either medium. This lack of activity of metronidazole against N. gonorrhoeae would suggest that the ability to recover N. gonorrhoeae in patients being treated with metronidazole for concurrent Trichomonas vaginalis infections should not be hampered. RESULTSMICs of metronidazole in Mueller-Hinton and chocolate agars against 64 gonococcal isolates, and the cumulative percent of organisms inhibited at each concentration, are summarized in Table 1. On either medium, all 64 isolates were resistant to metronidazole at 12.5
In vitro susceptibility of 100 clinical isolates of Neisseria gonorrhoeae to trimethoprim-sulfamethoxazole (TMP-SMZ combination; 1:19) was deternined by the agar dilution technique using three different media under similar conditions. On Oxoid diagnostic sensitivity test, Mueller-Hinton, and GC agar media, the percentage of isolates inhibited by 2.5 ug or less ofTMP per ml and 47.5 ,ug or less of SMZ per ml were 95, 90, and 84%, respectively. TMP-SMZ appeared to be effective in vitro against N. gonorrhoeae despite differences in the types of media used.Gonorrhea is presently a major infectious disease problem. The increased frequency of penicillin-resistant strains of Neisseria gonorrhoeae in uncomplicated infection (9,16,19) has made it imperative that clinicians seek other effective chemotherapeutic agents. Although tetracycline is effective in eradicating anogenital gonorrhea, resistance to this antibiotic is becoming increasingly apparent (2, 12). Similarly, spectinomycin-resistant strains ofN. gonorrhoeae have been isolated (12, 17). Moreover, cross-resistance to multiple antibiotics, including penicillin, tetracycline, spectinomycin, chloramphenicol, and erythromycin, is now being reported (10,12,15).Trimethoprim (2,4-diamino-5[3,4,5-trimethoxybenzyl]pyrimidine; TMP) in combination with a sulfonamide has demonstrated in vitro synergism in inhibiting growth of a variety of gramnegative bacillary organisms (1, 4, 7). Although preliminary in vitro data suggested that TMP plus sulfamethoxazole (SMZ) was also effective against N. gonorrhoeae (4, 7, 8, 13), a wide variety of media and conditions were used to obtain this information. The fastidious nature of the gonococcal organism, and the potential interaction of various media constituents with TMP-SMZ, make it imperative that a standardized method be utilized to meaningfully evaluate the efficacy of this agent against this bacterium. To investigate this problem, the in vitro susceptibility of 100 clinical isolates ofN. gonorrhoeae to TMP-SMZ, in a combination of one part TMP and 19 parts SMZ, was determined on three different media under similar conditions, using an agar dilution technique. and GC agars (BBL, GC agar base) were freshly prepared and enriched with 1% IsoVitaleX (BBL). Five-percent lysed horse blood (Scott Lab., Fiskeville, R.I.) was incorporated into each medium. The horse blood was lysed by the addition of 1:50 of a 10% saponin solution (7). Serial twofold dilutions of TMP and SMZ (provided by Hoffman LaRoche, Inc.) in a 1:19 combination starting with 5 ,ug of TMP per ml and 95 ug of SMZ per ml were prepared and incorporated into each medium. Susceptibility testing. Susceptibility ofN. gonorrhoeae to TMP-SMZ was determined by an agar dilution technique previously described (22). The organisms were thawed and subcultured on enriched chocolate agar for 24 h. Gonococcal suspensions were prepared in Mueller-Hinton broth from surface colonies on chocolate agar and adjusted to a McFarland no. 1 nephelometer standard (5), previously determined to appr...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.